Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma

• Published in: American journal of clinical oncology Vol. 42; no. 10; p. 755
• Main Authors: Lin, Chi, Verma, Vivek, Lazenby, Audrey, Ly, Quan P, Berim, Lyudmyla D, Schwarz, James K, Madiyalakan, Madi, Nicodemus, Christopher F, Hollingsworth, Michael A, Meza, Jane L, Are, Chandrakanth, Padussis, James, Grem, Jean L
• Format: Journal Article
• Language: English
• Published: United States 01.10.2019
• Subjects: Adenocarcinoma - diagnostic imaging; Adenocarcinoma - mortality; Adenocarcinoma - pathology; Adenocarcinoma - therapy; Adult; Aged; Antibodies, Monoclonal, Murine-Derived - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; CA-125 Antigen - blood; Camptothecin - adverse effects; Camptothecin - analogs & derivatives; Camptothecin - therapeutic use; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil - adverse effects; Fluorouracil - therapeutic use; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leucovorin - adverse effects; Leucovorin - therapeutic use; Magnetic Resonance Imaging - methods; Male; Membrane Proteins - blood; Middle Aged; Nelfinavir - adverse effects; Nelfinavir - therapeutic use; Neoadjuvant Therapy - methods; Neoplasm Invasiveness - pathology; Organoplatinum Compounds - adverse effects; Organoplatinum Compounds - therapeutic use; Pancreatic Neoplasms - diagnostic imaging; Pancreatic Neoplasms - mortality; Pancreatic Neoplasms - pathology; Pancreatic Neoplasms - therapy; Pancreaticoduodenectomy - methods; Proportional Hazards Models; Radiosurgery - methods; Risk Assessment; Survival Analysis; Time Factors; Tomography, X-Ray Computed - methods; Treatment Outcome

Cancer antigen (CA)-125 influences progression, metastasis, and outcomes in pancreatic cancer. This phase I/II trial (NCT01959672) evaluated the safety, efficacy, and immunologic correlates of chemoimmunotherapy (CIT) with oregovomab (anti-CA-125), followed by stereotactic body radiotherapy (SBRT) w...